A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress ...
Pharmaceutical Technology on MSN
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...
Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future ...
Despite considerable challenges, RNA interference (RNAi) as a therapeutic strategy continues to draw excitement and scrutiny. Two recent meetings—Select Biosciences’ “RNAi and miRNA World Congress” ...
The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...
Clinical translation of therapies based on small interfering RNA (siRNA) is hampered by siRNA’s comprehensively poor pharmacokinetic properties, which necessitate molecule modifications and complex ...
Tumours can avert an immune response and boost their own growth by inducing the expression of immunosuppressive, angiogenic and growth factors by neighbouring cells. Reporting in Nature Biotechnology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback